Table 4.
Comparative Kattan Nomogram Versus Kattan Plus BRCA Status
| Model and End Point | 5 Year |
8 Year |
10 Year |
|||
|---|---|---|---|---|---|---|
| AUC (%) | Likelihood Ratio Test P* | AUC (%) | Likelihood Ratio Test P* | AUC (%) | Likelihood Ratio Test P* | |
| All patients with local (N0 and M0) disease | ||||||
| Evaluable patients, n† | 927 | 521 | 267 | |||
| Metastasis-free survival | ||||||
| Kattan model | 81.1 | — | 76.2 | — | 76.6 | — |
| Kattan + BRCA | 82.5 | .048 | 76.6 | .128 | 77.8 | .143 |
| Cause-specific survival | ||||||
| Kattan model | 79.9 | — | 77.6 | — | 76.1 | — |
| Kattan + BRCA | 80.5 | .102 | 78.9 | .083 | 77.0 | .076 |
| Overall survival | ||||||
| Kattan model | 79.6 | — | 78.1 | — | 76.2 | — |
| Kattan + BRCA | 81.5 | .071 | 79.8 | .002 | 77.3 | .096 |
| Patients treated with prostatectomy for N0 and M0 disease | ||||||
| Evaluable patients, n† | 397 | 188 | 79 | |||
| Metastasis-free survival | ||||||
| Kattan model | 82.4 | — | 81.0 | — | 81.4 | — |
| Kattan + BRCA | 91.0 | .122 | 88.7 | .158 | 87.0 | .007 |
| Cause specific survival | ||||||
| Kattan model | 76.7 | — | 75.0 | — | 72.1 | — |
| Kattan + BRCA | 80.9 | .148 | 81.7 | .081 | 82.0 | .002 |
| Overall survival | ||||||
| Kattan model | 88.7 | — | 81.5 | — | 76.0 | — |
| Kattan + BRCA | 91.1 | .277 | 84.5 | .020 | 80.0 | .005 |
Abbreviation: AUC, area under the receiver operating characteristic curve.
*
Comparison of the logistic regression model for original Kattan nomogram alone (baseline prostate-specific antigen, Gleason score, and clinical tumor [T] stage) score versus the addition of BRCA carrier status using the likelihood ratio test.
†
All these survival analyses were handled as a simple binary variable for the logistic regression analyses. The number of patients for the different time points differs from the total of patients because those lost to follow-up before the end of the fixed time point were considered not to be evaluable for the analysis.